|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001367,
umls-concept:C0019704,
umls-concept:C0021311,
umls-concept:C0027361,
umls-concept:C0036849,
umls-concept:C0206558,
umls-concept:C0332307,
umls-concept:C1280500,
umls-concept:C1442518,
umls-concept:C1552652,
umls-concept:C1552685,
umls-concept:C1552961,
umls-concept:C1705195
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-8-5
|
|
pubmed:abstractText |
We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse-transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (P =.30) or CD4 cell counts (P =.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-10720507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-14624374,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-15031789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-17396995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-17957262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-18572080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-18779052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-18818198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-19509419,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-20009920,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-20089951,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-20214474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-7887550,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20649426-9537934
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1537-6613
|
|
pubmed:author |
pubmed-author:CelumConnieC,
pubmed-author:CoombsRobertR,
pubmed-author:CowanFrancesF,
pubmed-author:Delany-MoretlweSineadS,
pubmed-author:EshlemanSusan HSH,
pubmed-author:FuchsJonathanJ,
pubmed-author:HughesJamesJ,
pubmed-author:KhakiLeilaL,
pubmed-author:KimH NinaHN,
pubmed-author:McMahonMoira AMA,
pubmed-author:ReidStewartS,
pubmed-author:SanchezJorgeJ,
pubmed-author:SilicianoRobert FRF,
pubmed-author:WaldAnnaA,
pubmed-author:WangJingJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
202
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
734-8
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20649426-Acyclovir,
pubmed-meshheading:20649426-Adult,
pubmed-meshheading:20649426-Antibodies, Viral,
pubmed-meshheading:20649426-Antiviral Agents,
pubmed-meshheading:20649426-CD4 Lymphocyte Count,
pubmed-meshheading:20649426-Female,
pubmed-meshheading:20649426-HIV Infections,
pubmed-meshheading:20649426-HIV Reverse Transcriptase,
pubmed-meshheading:20649426-HIV-1,
pubmed-meshheading:20649426-Herpes Genitalis,
pubmed-meshheading:20649426-Herpesvirus 2, Human,
pubmed-meshheading:20649426-Humans,
pubmed-meshheading:20649426-Male,
pubmed-meshheading:20649426-RNA, Viral,
pubmed-meshheading:20649426-Treatment Outcome,
pubmed-meshheading:20649426-Viral Load,
pubmed-meshheading:20649426-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
|
|
pubmed:affiliation |
Department of Medicine, Schools of Medicine and Public Health, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA. hyangkim@uw.edu
|
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
